PCML
ESPR

Pavaki Capital Management LLC’s Esperion Therapeutics ESPR Stock Holding History

Pavaki Capital Management LLC’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-410,000
Closed -$1.12M – 167
2026
Q1 		$1.12M Buy
+410,000
New +$1.3M 0.48% 44

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $490M AUM 21.68% 1-Year Est. Return

Pavaki Capital Management LLC's ESPR Position: Q2 2026 in Review

Pavaki Capital Management LLC sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 410,000 shares — an estimated $1.12M sold.

Pavaki Capital Management LLC first reported a position in ESPR in Q1 2026 and held it in 1 quarter. The position peaked at $1.12M in Q1 2026. 67 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Pavaki Capital Management LLC reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Pavaki Capital Management LLC sold 410,000 Esperion Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Pavaki Capital Management LLC first reported a position in Esperion Therapeutics in Q1 2026 and held it in 1 quarter.
  • Pavaki Capital Management LLC's Esperion Therapeutics position peaked at $1.12M in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.